Treatment of resistance to Pazopanib

Pazopanib(Pazopanib) is an oral multi-target tyrosine kinase inhibitor widely used to treat malignant tumors such as renal cell carcinoma and soft tissue sarcoma. However, some patients may develop drug resistance after receiving pazopanib treatment, resulting in reduced therapeutic efficacy. But everyone’s constitution is different and their resistance to drugs is also different.

For patients treated with pazopanib, it is critical to regularly monitor tumors for biomarker and imaging changes. This helps to detect signs of resistance early and to take appropriate treatment measures in a timely manner. When a patient develops resistance to pazopanib, he or she should communicate with the doctor in a timely manner, and the doctor may suggest trying to replace it with other effective targeted drugs. Such as sorafenib (Sorafenib), axitinib (Axitinib), etc. are commonly used alternative drug options. Switching drugs can delay the development of drug resistance by inhibiting different signaling pathways.

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.